title: Reversing Halt, FDA reauthorizes sale of ponatinib.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Roth
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D011724:Pyridazines / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D011724:Pyridazines; C545373:ponatinib